Table 1

Baseline patient characteristics, treatment selections and clinical outcomes

Characteristic/Clinical responsePatients (total n=34)
Age, median (range)61 (41–79)
Male sex, n (%)20 (59)
ECOG PS score, n (%)
 08 (24)
 117 (50)
 27 (21)
 31
 Unknown1
IMDC risk score, n (%)
 04 (12)
 112 (35)
 214 (41)
 33 (9)
 41 (3)
Tissue specimen, n (%)
 Primary24 (71)
 Metastatic10 (29)
Line of therapy, n (%)
 First line4 (12)
 Second line15 (44)
 Third line or after15 (44)
Checkpoint inhibitor treatment, n (%)
 Nivolumab31 (91)
 Ipilimumab/Nivolumab2 (6)
 Pembrolizumab1 (3)
Number of doses, median (range)9.5 (1–56)
Time on ICI, median (range)4.8 months (0–24)
Follow-up, median (range)9.1 months (1–31)
Best response (n; %)
 Disease control (n=16; 47%)
  Complete response2 (6)
  Partial response5 (15)
  Stable disease9 (26)
 Progressive disease (n=18; 53%)
  Progressive disease18 (53)
Treatment discontinuation reason
 Disease progression24
 Immune-mediated toxicity2
  • ECOG, Eastern Cooperative Oncology Group.